Purpose of the study Statins and ezetimibe reduce low-density lipoprotein cholesterol (LDL-c) and cardiovascular disease (CVD) risk. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors lower LDL-c by 50%-70% and might be useful in refractory patients. The National Institute for Health and Care Excellence (NICE) technology appraisal guidance (TAG) recommends use of these drugs in secondary prevention and familial hypercholesterolaemia (FH) at differing LDL-c thresholds.
INTRODUCTION
The association between cardiovascular disease (CVD) risk and raised serum total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-c) has been demonstrated in epidemiology studies, 1 2 and intervention trials showing significant decreases in CVD following use of LDL-c reducing agents such as statins and ezetimibe. Following the Scandinavian Simvastatin Survival Study (4S) in 1994, statins have been the mainstay of lipid-lowering treatments. 3 Since 1998 various secondary prevention targets have been proposed based on interventional trials. [4] [5] [6] [7] [8] [9] [10] [11] As a result, the Quality and Outcomes Framework, a UK primary care incentive scheme, has introduced targets of TC <5 mmol/L and LDL-c <3 mmol/L. 12 Further, lower targets that also include non-high-density lipoprotein cholesterol (HDL-c) have been presented by the Joint British Society in 2014. 13 These indicate a non-HDL-c target of <2.5 mmol/L (considered equivalent to an LDL-c <1.8 mmol/L).
However, despite the increasing efficacy of the newer statins, many patients do not achieve LDL-c targets. 14 The introduction of ezetimibe in 2002 offered a further treatment route. 15 16 Intervention trials with ezetimibe (used with statins) such as SHARP and IMPROVE-IT led to CVD benefits in keeping with LDL-c reduction and suggested that LDL-c reduction, regardless of treatment, will affect a reduction in CVD. 17 18 However, even with combination treatment, some patients fail to achieve targets. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are monoclonal antibodies that inactivate PCSK9 leading to decreased LDL receptor degradation and increased LDL uptake. Alirocumab and evolocumab were licensed in 2015 and, given as monotherapy or with statins, affected LDL-c reductions of 50%-70%. 19 20 However, with an annual UK cost of over £4000/patient (both agents), the affordability of these drugs had been questioned. Following an undisclosed price discount (both drugs) the technology appraisal guidance (TAG) (https://www.nice.org.uk/guidance/ta393, https:// www.nice.org.uk/guidance/ta394) issued by The National Institute for Health and Care Excellence (NICE) recommends use of PCSK inhibitors (in the event of provision at a discounted price) in secondary prevention and heterozygous familial hypercholesterolaemia (FH). In secondary prevention, LDL-c treatment thresholds of 4.0 and 3.5 mmol/L are recommended in patients considered high risk (history of acute coronary syndrome, coronary or other arterial revascularisation procedures, chronic heart disease, ischaemic stroke, peripheral arterial disease) and very high risk (recurrent cardiovascular events or cardiovascular events in more than one vascular bed) of CVD, respectively, following the use of maximally tolerated statins and ezetimibe. In contrast, an LDL-c threshold >5.0 mmol/L was recommended in FH after statin/ezetimibe treatment.
There is little data from routine care on the numbers of patients who do not meet lipid targets following maximal treatment. In 2009 we carried out a case-note audit estimating the efficacy of ezetimibe and now describe the use of these data to estimate the number of patients in a secondary care outpatient clinic who might be suitable for treatment with a PCSK9 inhibitor at different cut-off levels.
MATERIALS AND METHODS
The Lipid and Metabolic Clinic in the Heart of England Foundation NHS Trust serves a primary care catchment of 440 000 people and treats patients not achieving target lipid levels and/or experiencing side effects from lipid-lowering therapy (figure 1). In our NHS region neither rosuvastatin nor ezetimibe can be prescribed in primary care without local lipid clinic recommendation. Between April 2007 and March 2008, 271 patients were referred to the clinic and 72 of these patients were started on ezetimibe when not achieving target TC and/or LDL-c levels on maximal statin treatment (table 1) . Data on these patients were collected as part of the lipid clinic audit programme carried out by the Department of Clinical Biochemistry, Heart of England Foundation NHS Trust to evaluate guideline compliance and efficacy of lipid-lowering agents (statins, fibrates, ezetimibe). 21 22 In the clinic we tried to achieve targets of TC: 4 mmol/L and/or LDL-c: 2 mmol/L. Treatment preceded the NICE guidance for FH management in 2008 (https://www. nice.org.uk/guidance/cg71). Table 1 shows treatment details in these patients.
TC, triglyceride (TG) and HDL-c levels were measured using the Roche Modular platform P800 analyser with Roche reagents in the Department of Clinical Biochemistry at Good Hope Hospital. LDL-c was calculated on the laboratory computer system when TG levels were <4.5 mmol/L. The audit data were transferred from an Excel spreadsheet to Stata V.8 (College Station, Texas, USA) and patient distribution of TC and LDL-c levels post-statin and/or ezetimibe treatment calculated. Table 1 shows changes in lipids following treatment in the total cohort and subgroups. In the total group (n=72), mean TC pretreatment ( post-lifestyle intervention) was 8.5 mmol/L and mean LDL-c (available in only the 63 patients who did not have 
RESULTS

DISCUSSION
We used data collected in 2009 from a clinical audit on ezetimibe efficacy to estimate using different TC and LDL-c thresholds, the numbers of patients who might be eligible for a PCSK9 inhibitor. This audit has limitations; patient numbers were small and they were seen because of clinical need and not a study protocol. However, decisions on PCSK9 inhibitor use will need to be compatible with an outpatient setting. Thus, we suggest that our approach is valid.
The critical role of LDL-c in determining risk is shown by meta-analysis of 14 trials comprising 90 000 individuals; LDL-c reduction of 1 mmol/L conferred a reduction in relative coronary heart disease risk of 23%. 23 Further, the additive effect of combinations of drugs that reduce LDL-c levels by different mechanisms is shown by IMPROVE-IT. 23 A meta-analysis (seven trials, 31 048 patients) by Savarese et al 24 suggested addition of ezetimibe significantly reduced myocardial infarction and stroke, but not overall and cardiovascular mortality.
PCSK9 inhibitors are effective; they lower serum LDL-c levels by 50%-70% 19 20 and reduce myocardial infarction and allcause mortality. 25 Clearly, while PCSK9 inhibitors might be effective, their cost demands consideration of which patients should receive them. In particular, the relationship between baseline LDL-c, the extent of LDL-c reduction and health benefit needs consideration.
Our data suggest that patient numbers eligible for PCSK9 inhibitors are modest. There are various reasons for this. All patients attended the lipid clinic and all available statins were tried. Many patients were prescribed statins with long half-lives at non-daily frequency. Some patients purchased coenzyme Q10 supplements and reported improved statin-related tolerability. This suggests that all prescription of PCSK9 inhibitors should be through specialist lipid clinics. Study limitations include the small sample size and lack of outcome data. Further, we could not stratify our patients as high or very high risk as defined by NICE. We speculate that there would be an accumulating cohort of patients not having met LDL-c levels over many years who will require PSCK9 inhibitors soon after the NICE final approval. Once these patients are treated we expect new prescriptions to fall to the figures described in this study.
Clearly, current guidance on PCSK9 usage is based on limited information on efficacy and adverse effects, and no outcome data (eg, CVD/mortality) are available. Thus, randomised controlled studies and longitudinal observational studies are required with CVD/mortality as end points. It is also important that benefits in conditions not specified by NICE, such as individuals with metabolic syndrome/type 2 diabetes, are also evaluated. Adverse event data must be collected from trials and routine use. Once these are available, re-evaluation of LDL-c thresholds in various high-risk patients can be carried out.
Main messages
▸ The number of patients requiring third-line treatment with a PCSK9 inhibitor appears to be small. ▸ Effective clinical use and cost efficiency are best achieved by restricting PCSK9 inhibitor prescription to clinicians specialising in treating dyslipidaemia. ▸ While use of PCSK9 inhibitors may be relatively large initially, once the backlog of patients currently requiring third-line intervention is cleared, prescribing will fall as only newly diagnosed patients will require treatment.
Current research questions
▸ Outcome studies of PCSK9 inhibitor treatment with cardiovascular disease (CVD)/mortality as end points are needed. ▸ Adverse effects of PCSK9 inhibitors need to be assessed in routine clinical use. ▸ Efficacy and CVD outcomes in patients not currently specified by National Institute for Health and Care Excellence (eg, metabolic syndrome/type 2 diabetes) require study.
